Telix Pharmaceuticals to Acquire European Production Facility

Melbourne (Australia) and Brussels (Belgium) – 3 October 2019. Telix announces that it has entered into a conditional purchase agreement with Eckert & Ziegler Strahlen

Telix is pleased to announce that it has entered into a conditional purchase agreement with Eckert & Ziegler Strahlen and Medizintechnik Aktiengesellschaft to acquire a licensed radiopharmaceutical production facility in Seneffe, Belgium.

Telix expects that its future European manufacturing needs will be met by the acquisition of the Site. In the Americas and Asia/Pacific regions, Telix has established partnerships with leading firms that have sufficient manufacturing capacity to support commercialisation. In contrast, the European radiopharmaceutical manufacturing landscape is fragmented and lacks the scale-up production capacity to deliver Telix’s needs across its product portfolio.

The timing of this acquisition is important as the Company expects to complete two European product launches in the next 18-24 months (subject to regulatory approvals) and there is significant lead-time to complete the necessary regulatory and compliance requirements for the Site. Telix expects to continue to work with key existing EU contract manufacturing partners for both backup manufacturing and product delivery in certain territories where existing production solutions may be adequate.

CEO Dr. Christian Behrenbruch stated, “This is a big step forward for Telix, but it is a commercially necessary step given the Company’s commercial trajectory over the next two years. The Site is unique in both the depth of the license and its operational fit with our entire product portfolio. We’d like to acknowledge the excellent support and advice from a multitude of Belgian regulatory, science & technology, and economic development agencies that have worked very closely with us to validate the business case for this transaction.”

To read the full media release click here.